Guido Oelkers is a businessperson who has been at the helm of 8 different companies. Dr. Oelkers is President & Chief Executive Officer for Swedish Orphan Biovitrum AB, Chief Executive Officer of BSN medical BV and Chief Executive Officer & Director at BSN medical International Holding GmbH & Co. KG. He is also on the board of Dova Pharmaceuticals, Inc. and Swedish Orphan Biovitrum, Inc.
In the past Guido Oelkers occupied the position of Group Chief Executive Officer of BSN medical GmbH, Chief Executive Officer at BSN Medical Holding, President & Chief Executive Officer at Gambro AB, President & Chief Executive Officer for Gambro Lundia AB, Chief Executive Officer of Invida Group Pte Ltd., Executive Vice President-Commercial Operations at Takeda A, Principal at Aventis Pharma Deutschland GmbH and Executive Vice President-Commercial Operations at Takeda Pharmaceuticals International GmbH.
Dr. Oelkers received a doctorate from the University of South Australia and a graduate degree from London South Bank University.